Explanipedia

Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1 Open

Thuy Tran, Gabriela Athziri Sánchez‐Zuno, Lais Osmani, Jasmine I. Caulfield, Caroline Naomi Valdez , et al. · 2025

Macrophage migration inhibitory factor (MIF) is an upstream regulatory cytokine that is associated with advanced disease and poor outcomes in multiple cancer types, including melanoma. We investigated whether anti-MIF therapy could enhance…

Next-gen tools in cancer neuroscience Open

Vera Thiel, Debpali Sur, Caroline C. Picoli, Tamara McErlain, Katalina Couto , et al. · 2025

The emerging field of cancer neuroscience is rapidly evolving, driven by novel technologies and tools. These include advances in single-cell and spatial transcriptomics; genetic mouse models paired with automated high-throughput; and innov…

0426 UAZ22-10-01: A Phase IIa single-arm open-label clinical trial of calcipotriene plus 5-fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients Open

Marjan Azin, Tomonori Oka, Chi-Pin Hsu, Jacques Malo, Kassem Safa , et al. · 2025

<span>MIF</span> as an oncogenic driver of low‐heterogeneity melanomas Open

Thuy Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Noam Savion‐Gaiger, Richard Bucala · 2025

Identifying targets involved in tumor evolution and immune escape is an active area of research in oncology. Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine that promotes transformed cell proliferation…

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy Open

Rosalyn M. Fey, Avery Billo, Terri Clister, K Doan, Elizabeth Berry , et al. · 2025

In the era of precision medicine, mounting evidence suggests that the time of therapy administration, or chronotherapy, has a great impact on treatment outcomes. Chronotherapy involves planning treatment timing by considering circadian rhy…

Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma Open

Caroline Naomi Valdez, Gabriela Athziri Sánchez‐Zuno, Lais Osmani, Wael Ibrahim, Anjela Galan , et al. · 2024

Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a variety of cancers. Recent evidence suggests MIF as a therapeutic target in immune ch…

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy Open

Rosalyn M. Fey, Rebecca A. Nichols, Thuy Tran, Arthur A. Vandenbark, Rajan P. Kulkarni · 2024

Immune checkpoint blockade (ICB) therapy is used to treat a wide range of cancers; however, some patients are at risk of developing treatment resistance and/or immune-related adverse events (irAEs). Thus, there is a great need for the iden…

Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers Open

Zachary R. Garrison, Terri Clister, Eric Bleem, Elizabeth Berry, Rajan P. Kulkarni · 2024

BRAF-mutant melanoma patients can be treated with targeted therapy or immunotherapies, and it is not clear which should be provided first. Targeted treatments do not work in up to one-third of cases, while immunotherapies may only be effec…

Optimization of Tissue Digestion Methods for Characterization of Photoaged Skin by Single Cell RNA Sequencing Reveals Preferential Enrichment of T Cell Subsets Open

Terri Clister, Rosalyn M. Fey, Zachary R. Garrison, Cristian D. Valenzuela, Anna Bar , et al. · 2024

Healthy human skin tissue is often used as a control for comparison to diseased skin in patients with skin pathologies, including skin cancers or other inflammatory conditions such as atopic dermatitis or psoriasis. Although non-affected s…

Computational assessment of T cell plasticity in immune-related adverse events Open

Rosalyn M. Fey, Rajan P. Kulkarni · 2024

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy Open

Inga Van Buren, Cecelia J. Madison, Aimee D. Kohn, Elizabeth Berry, Rajan P. Kulkarni , et al. · 2023

Importance Systemic steroids are commonly used to manage immune-related adverse events (irAEs), but it remains unclear whether they may undermine immune checkpoint inhibitor (ICI) therapy outcomes. Few studies have assessed the impact of s…

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 Open

Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth I. Buchbinder, Diwakar Davar, Geoffrey T. Gibney , et al. · 2023

Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combi…

Advances in Early Detection of Melanoma and the Future of At-Home Testing Open

Zachary R. Garrison, Connor M. Hall, Rosalyn M. Fey, Terri Clister, Nabeela Khan , et al. · 2023

The past decade has seen numerous advancements in approaches to melanoma detection, each with the common goal to stem the growing incidence of melanoma and its mortality rate. These advancements, while well documented to increase early mel…

Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation Open

Frederick R. Adler, Alexander R.A. Anderson, Abhinav Bhushan, Paul Bogdan, Jose Javier Bravo‐Cordero , et al. · 2023

Early Detection and Prognostic Assessment of Cutaneous Melanoma Open

Mohammed Kashani‐Sabet, Sancy A. Leachman, Jennifer Stein, Jack L. Arbiser, Elizabeth Berry , et al. · 2023

Importance Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use of pigmented lesion eval…

A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events Open

Zachary R. Garrison, Matthew E.K. Chang, Noah I. Hornick, Wesley Y. Yu, Jeffrey B. Cheng , et al. · 2022

Immune related adverse events (irAEs) are one of the leading causes of discontinuation of cancer immunotherapy treatment. Despite extensive research into the frequency and types of irAEs, little is known about the cell types and pathways t…

Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells Open

Reilly G. Fankhauser, Matthew Chang, Zachary R. Garrison, Rachel Berryman, Olivia M. Lucero , et al. · 2022

The current standard for investigating tumors is surgical biopsy, which is costly, invasive, and difficult to perform serially. As an adjunct, circulating tumor cells (CTCs)—cells that have broken away from the primary tumor or metastatic …

Slip versus Slop: A Head-to-Head Comparison of UV-Protective Clothing to Sunscreen Open

Elizabeth Berry, Joshua Bezecny, Michael R. Acton, Taylor P. Sulmonetti, David M. Anderson , et al. · 2022

Ultraviolet radiation (UVR) exposure is the most important modifiable risk factor for skin cancer development. Although sunscreen and sun-protective clothing are essential tools to minimize UVR exposure, few studies have compared the two m…

Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic Open

Brock A. Humphries, Priscilla Y. Hwang, Agnieszka A. Kendrick, Rajan P. Kulkarni, Rachel Pozzar , et al. · 2021

Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma Open

Wesley Y. Yu, Sheena T. Hill, E. Ricky Chan, John J. Pink, Kevin D. Cooper , et al. · 2021

Bidirectional interconversion between mutually exclusive tumorigenic and drug-tolerant melanoma cell phenotypes Open

Yuntian Zhang, R.L. Belote, Marcus Urquijo, Maike M. K. Hansen, Miroslav Hejna , et al. · 2020

Human cancers can exhibit phenotype switching, resulting in cells that are more metastatic or that are more tolerant to treatment. However, the relationship between these aggressive states is not well understood. We investigated the dynami…

p38 Mitogen-activated protein kinase regulates chamber-specific perinatal growth in heart Open

Tomohiro Yokota, Jin Li, Jijun Huang, Zhaojun Xiong, Qing Zhang , et al. · 2020

In the mammalian heart, the left ventricle (LV) rapidly becomes more dominant in size and function over the right ventricle (RV) after birth. The molecular regulators responsible for this chamber-specific differential growth are largely un…

Circulating biomarkers predictive of tumor response to cancer immunotherapy Open

Ernest Y. Lee, Rajan P. Kulkarni · 2019

Introduction: The advent of checkpoint blockade immunotherapy has revolutionized cancer treatment, but clinical response to immunotherapies is highly heterogeneous among individual patients and between cancer types. This represents a chall…

Endocardially Derived Macrophages Are Essential for Valvular Remodeling Open

Ayako Shigeta, Vincent Huang, Jonathan Zuo, Rana H. Besada, Yasuhiro Nakashima , et al. · 2019

Multiscale light-sheet for rapid imaging of cardiopulmonary system Open

Yichen Ding, Jianguo Ma, Adam D. Langenbacher, Kyung In Baek, Juhyun Lee , et al. · 2018

The ability to image tissue morphogenesis in real-time and in 3-dimensions (3-D) remains an optical challenge. The advent of light-sheet fluorescence microscopy (LSFM) has advanced developmental biology and tissue regeneration research. In…

MP64-16 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY INCREASES BOTH TUMOR-INFILTRATING LYMPHOCYTES AND SUPPRESSIVE IMMUNE CELLS IN PROSTATE CANCER Open

Lin Lin, Nathan Kane, Naoko Kobayashi, Siliva Diaz-Perez, Rajan P. Kulkarni , et al. · 2018

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology II1 Apr 2018MP64-16 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY INCREASES BOTH TUMOR-INFILTRATING LYMPHOCYTES AND SUPPRESSIVE IMMUNE CELLS IN PROSTATE CANCER…

Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice Open

Jeffrey J. Hsu, Jinxiu Lu, Soban Umar, Jason T. Lee, Rajan P. Kulkarni , et al. · 2018

Calcific aortic vasculopathy correlates with bone loss in osteoporosis in an age-independent manner. Prior work suggests that teriparatide, the bone anabolic treatment for postmenopausal osteoporosis, may inhibit the onset of aortic calcif…

Analysis of cardiomyocyte clonal expansion during mouse heart development and injury Open

Konstantina-Ioanna Sereti, Ngoc B. Nguyen, Paniz Kamran, Peng Zhao, Sara Ranjbarvaziri , et al. · 2018

The cellular mechanisms driving cardiac tissue formation remain poorly understood, largely due to the structural and functional complexity of the heart. It is unclear whether newly generated myocytes originate from cardiac stem/progenitor …

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer Open

Manjima Dhar, J. Wong, James Che, Melissa Matsumoto, Tristan Grogan , et al. · 2018

Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression …

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management Open

John Shen, Jason Y.H. Chang, Melody Mendenhall, Grace Cherry, Jonathan W. Goldman , et al. · 2018

Background: The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies have shown exceptional activity in many cancers. However, these immunotherapies can also result in diverse adverse cutaneou…

Rajan P. Kulkarni YOU? Author Swipe